vs
Side-by-side financial comparison of Primis Financial Corp. (FRST) and GYRE THERAPEUTICS, INC. (GYRE). Click either name above to swap in a different company.
Primis Financial Corp. is the larger business by last-quarter revenue ($45.6M vs $37.2M, roughly 1.2× GYRE THERAPEUTICS, INC.). Primis Financial Corp. runs the higher net margin — 16.0% vs -3.7%, a 19.7% gap on every dollar of revenue. Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs 13.0%).
Primis Financial Corp is a U.S.-based financial holding company operating full-service banking subsidiaries. It provides a comprehensive range of financial solutions including personal and commercial deposit products, diverse loan facilities, mortgage services, and wealth management support, primarily serving retail and corporate customers across the U.S. mid-Atlantic region.
GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.
FRST vs GYRE — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $45.6M | $37.2M |
| Net Profit | $7.3M | $-1.4M |
| Gross Margin | — | 95.3% |
| Operating Margin | — | 0.3% |
| Net Margin | 16.0% | -3.7% |
| Revenue YoY | — | 33.4% |
| Net Profit YoY | 200.0% | -340.1% |
| EPS (diluted) | $0.30 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $45.6M | — | ||
| Q4 25 | $80.9M | $37.2M | ||
| Q3 25 | $41.0M | $30.6M | ||
| Q2 25 | $43.2M | $26.8M | ||
| Q1 25 | $58.7M | $22.1M | ||
| Q4 24 | $38.8M | $27.9M | ||
| Q3 24 | $37.3M | $25.5M | ||
| Q2 24 | $35.7M | $25.2M |
| Q1 26 | $7.3M | — | ||
| Q4 25 | $29.5M | $-1.4M | ||
| Q3 25 | $6.8M | $5.9M | ||
| Q2 25 | $2.4M | $1.6M | ||
| Q1 25 | $22.6M | $3.7M | ||
| Q4 24 | $-26.2M | $569.0K | ||
| Q3 24 | $1.2M | $2.9M | ||
| Q2 24 | $3.4M | $4.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 95.3% | ||
| Q3 25 | — | 94.7% | ||
| Q2 25 | — | 95.7% | ||
| Q1 25 | — | 95.9% | ||
| Q4 24 | — | 95.8% | ||
| Q3 24 | — | 96.2% | ||
| Q2 24 | — | 96.9% |
| Q1 26 | — | — | ||
| Q4 25 | 44.8% | 0.3% | ||
| Q3 25 | 21.3% | 22.7% | ||
| Q2 25 | 6.9% | 8.1% | ||
| Q1 25 | 41.9% | 10.3% | ||
| Q4 24 | -123.0% | 2.4% | ||
| Q3 24 | -3.1% | 16.6% | ||
| Q2 24 | 7.8% | 12.7% |
| Q1 26 | 16.0% | — | ||
| Q4 25 | 36.5% | -3.7% | ||
| Q3 25 | 16.7% | 19.4% | ||
| Q2 25 | 5.6% | 5.9% | ||
| Q1 25 | 38.6% | 16.9% | ||
| Q4 24 | -100.3% | 2.0% | ||
| Q3 24 | 3.3% | 11.2% | ||
| Q2 24 | 9.6% | 18.0% |
| Q1 26 | $0.30 | — | ||
| Q4 25 | $1.19 | $-0.01 | ||
| Q3 25 | $0.28 | $0.03 | ||
| Q2 25 | $0.10 | $0.00 | ||
| Q1 25 | $0.92 | $0.00 | ||
| Q4 24 | $-0.95 | $0.00 | ||
| Q3 24 | $0.05 | $0.01 | ||
| Q2 24 | $0.14 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $159.9M | $52.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $427.2M | $106.0M |
| Total Assets | $4.3B | $166.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $159.9M | — | ||
| Q4 25 | $143.6M | $52.4M | ||
| Q3 25 | $63.9M | $60.0M | ||
| Q2 25 | $94.1M | $54.4M | ||
| Q1 25 | $57.0M | $29.9M | ||
| Q4 24 | $64.5M | $26.7M | ||
| Q3 24 | $77.3M | $25.1M | ||
| Q2 24 | $66.6M | $25.1M |
| Q1 26 | $427.2M | — | ||
| Q4 25 | $422.9M | $106.0M | ||
| Q3 25 | $382.2M | $101.9M | ||
| Q2 25 | $376.4M | $92.0M | ||
| Q1 25 | $375.6M | $68.1M | ||
| Q4 24 | $351.8M | $63.3M | ||
| Q3 24 | $381.0M | $63.2M | ||
| Q2 24 | $376.0M | $60.4M |
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.0B | $166.1M | ||
| Q3 25 | $4.0B | $159.4M | ||
| Q2 25 | $3.9B | $152.6M | ||
| Q1 25 | $3.7B | $129.8M | ||
| Q4 24 | $3.7B | $125.4M | ||
| Q3 24 | $4.0B | $125.2M | ||
| Q2 24 | $4.0B | $120.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-5.6M |
| Free Cash FlowOCF − Capex | — | $-5.8M |
| FCF MarginFCF / Revenue | — | -15.5% |
| Capex IntensityCapex / Revenue | — | 0.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-180.0K |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $10.8M | $-5.6M | ||
| Q3 25 | $-11.4M | $4.7M | ||
| Q2 25 | $-41.0M | $2.1M | ||
| Q1 25 | $34.4M | $-129.0K | ||
| Q4 24 | $19.5M | $-2.8M | ||
| Q3 24 | $6.1M | $1.7M | ||
| Q2 24 | $52.3M | $-5.5M |
| Q1 26 | — | — | ||
| Q4 25 | $9.0M | $-5.8M | ||
| Q3 25 | — | $4.0M | ||
| Q2 25 | — | $1.8M | ||
| Q1 25 | — | $-251.0K | ||
| Q4 24 | $18.3M | $-2.8M | ||
| Q3 24 | — | $1.0M | ||
| Q2 24 | — | $-6.9M |
| Q1 26 | — | — | ||
| Q4 25 | 11.2% | -15.5% | ||
| Q3 25 | — | 13.1% | ||
| Q2 25 | — | 6.8% | ||
| Q1 25 | — | -1.1% | ||
| Q4 24 | 47.3% | -10.1% | ||
| Q3 24 | — | 4.1% | ||
| Q2 24 | — | -27.5% |
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | 0.4% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | 3.1% | 0.2% | ||
| Q3 24 | 0.0% | 2.7% | ||
| Q2 24 | 0.0% | 5.8% |
| Q1 26 | — | — | ||
| Q4 25 | 0.36× | — | ||
| Q3 25 | -1.67× | 0.79× | ||
| Q2 25 | -16.82× | 1.32× | ||
| Q1 25 | 1.52× | -0.03× | ||
| Q4 24 | — | -4.85× | ||
| Q3 24 | 4.93× | 0.60× | ||
| Q2 24 | 15.21× | -1.21× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FRST
| Net Interest Income | $32.1M | 70% |
| Noninterest Income | $13.6M | 30% |
GYRE
Segment breakdown not available.
